Third quarter worldwide revenue increased slightly by 0.8% year-over-year to $38.5 million.
Updated 2023 revenue guidance to approximately $165 million, marking a 2% increase over 2022.
Loss from operations widened to $21.0 million from $10.5 million in the same quarter last year.
Net loss for the quarter expanded to $29.3 million compared to $18.6 million in the year-ago period
On November 7, 2023, Establishment Labs Holdings Inc (NASDAQ:ESTA), a leader in medical technology for women's health, announced its financial results for the third quarter ended September 30, 2023. Despite a modest increase in revenue, the company faced a challenging quarter with a significant increase in operating losses and net losses compared to the same period last year. The financial details were disclosed in conjunction with the company's earnings release and will be further discussed in the quarterly report on Form 10-Q to be filed on November 8, 2023.
Financial Performance Overview
Establishment Labs reported a slight year-over-year revenue increase to $38.5 million in the third quarter, attributing the growth to its diverse product portfolio. However, the company experienced a downturn in demand for breast procedures globally, which impacted its financial performance. The updated revenue guidance for 2023 is set at approximately $165 million, a 2% increase over the previous year, reflecting cautious optimism amidst market challenges.
Operational Challenges and Strategic Focus
CEO Juan Jose Chacon-Quiros acknowledged the industry's cyclical nature and the transient reduced demand. He emphasized the company's strategic focus on growth initiatives, particularly the U.S. and China launch of Motiva and the global rollout of Mia Femtech. Chacon-Quiros expressed confidence in the company's foundation and its $500 million revenue target for 2026.
Our results in the third quarter and updated guidance reflect lower demand for breast procedures globally," said Juan Jose Chacon-Quiros, Chief Executive Officer. "With our core platform and our pipeline of new products, we are taking market share globally and this should continue through the remainder of 2023 and into 2024."
https://finance.yahoo.com/news/establishment-labs-holdings-inc-esta-221157233.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.